Uniphar (UPR) Competitors

Mediclinic International pays an annual dividend of GBX 3 per share. Uniphar pays an annual dividend of GBX 1.96 per share and has a dividend yield of 0.5%. Mediclinic International pays out 1,304.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Uniphar pays out 10.1% of its earnings in the form of a dividend. Uniphar is clearly the better dividend stock, given its higher yield and lower payout ratio.

Mediclinic International has a net margin of 4.99% compared to Uniphar's net margin of 1.66%. Uniphar's return on equity of 13.14% beat Mediclinic International's return on equity.

Mediclinic International has higher revenue and earnings than Uniphar. Mediclinic International is trading at a lower price-to-earnings ratio than Uniphar, indicating that it is currently the more affordable of the two stocks.

In the previous week, Mediclinic International's average media sentiment score of 0.00 equaled Uniphar'saverage media sentiment score.

39.2% of Mediclinic International shares are held by institutional investors. Comparatively, 34.7% of Uniphar shares are held by institutional investors. 48.9% of Mediclinic International shares are held by company insiders. Comparatively, 7.6% of Uniphar shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Mediclinic International has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market. Comparatively, Uniphar has a beta of 1.126, meaning that its stock price is 13% more volatile than the broader market.

Uniphar has a consensus price target of GBX 427.50, indicating a potential upside of 6.88%. Given Uniphar's stronger consensus rating and higher possible upside, analysts plainly believe Uniphar is more favorable than Mediclinic International.

Hikma Pharmaceuticals has a beta of 0.643, suggesting that its share price is 36% less volatile than the broader market. Comparatively, Uniphar has a beta of 1.126, suggesting that its share price is 13% more volatile than the broader market.

63.6% of Hikma Pharmaceuticals shares are held by institutional investors. Comparatively, 34.7% of Uniphar shares are held by institutional investors. 17.3% of Hikma Pharmaceuticals shares are held by insiders. Comparatively, 7.6% of Uniphar shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Hikma Pharmaceuticals has a net margin of 12.00% compared to Uniphar's net margin of 1.66%. Hikma Pharmaceuticals' return on equity of 15.83% beat Uniphar's return on equity.

Hikma Pharmaceuticals has higher revenue and earnings than Uniphar. Hikma Pharmaceuticals is trading at a lower price-to-earnings ratio than Uniphar, indicating that it is currently the more affordable of the two stocks.

In the previous week, Hikma Pharmaceuticals had 2 more articles in the media than Uniphar. MarketBeat recorded 2 mentions for Hikma Pharmaceuticals and 0 mentions for Uniphar. Hikma Pharmaceuticals' average media sentiment score of 0.37 beat Uniphar's score of 0.00 indicating that Hikma Pharmaceuticals is being referred to more favorably in the media.

Hikma Pharmaceuticals pays an annual dividend of GBX 84.14 per share and has a dividend yield of 5.7%. Uniphar pays an annual dividend of GBX 1.96 per share and has a dividend yield of 0.5%. Hikma Pharmaceuticals pays out 46.5% of its earnings in the form of a dividend. Uniphar pays out 10.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Hikma Pharmaceuticals currently has a consensus price target of GBX 2,128, suggesting a potential upside of 43.98%. Uniphar has a consensus price target of GBX 427.50, suggesting a potential upside of 6.88%. Given Hikma Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Hikma Pharmaceuticals is more favorable than Uniphar.

Uniphar has higher revenue and earnings than Abcam. Abcam is trading at a lower price-to-earnings ratio than Uniphar, indicating that it is currently the more affordable of the two stocks.

Uniphar has a net margin of 1.66% compared to Abcam's net margin of 0.00%. Uniphar's return on equity of 13.14% beat Abcam's return on equity.

Uniphar currently has a consensus target price of GBX 427.50, suggesting a potential upside of 6.88%. Given Uniphar's stronger consensus rating and higher probable upside, equities analysts plainly believe Uniphar is more favorable than Abcam.

In the previous week, Uniphar's average media sentiment score of 0.00 equaled Abcam'saverage media sentiment score.

34.7% of Uniphar shares are held by institutional investors. 7.6% of Uniphar shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Uniphar currently has a consensus price target of GBX 427.50, suggesting a potential upside of 6.88%. Given Uniphar's stronger consensus rating and higher probable upside, analysts clearly believe Uniphar is more favorable than Indivior.

Uniphar has higher revenue and earnings than Indivior. Indivior is trading at a lower price-to-earnings ratio than Uniphar, indicating that it is currently the more affordable of the two stocks.

34.7% of Uniphar shares are held by institutional investors. Comparatively, 86.0% of Indivior shares are held by institutional investors. 7.6% of Uniphar shares are held by company insiders. Comparatively, 3.4% of Indivior shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Uniphar pays an annual dividend of GBX 1.96 per share and has a dividend yield of 0.5%. Indivior pays an annual dividend of GBX 15 per share and has a dividend yield of 1.2%. Uniphar pays out 10.1% of its earnings in the form of a dividend. Indivior pays out -1,243.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Indivior is clearly the better dividend stock, given its higher yield and lower payout ratio.

Indivior has a net margin of 14.30% compared to Uniphar's net margin of 1.66%. Uniphar's return on equity of 13.14% beat Indivior's return on equity.

Uniphar has a beta of 1.126, meaning that its share price is 13% more volatile than the broader market. Comparatively, Indivior has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market.

In the previous week, Indivior had 1 more articles in the media than Uniphar. MarketBeat recorded 1 mentions for Indivior and 0 mentions for Uniphar. Indivior's average media sentiment score of 1.25 beat Uniphar's score of 0.00 indicating that Indivior is being referred to more favorably in the news media.